16 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of KDM5A inhibitors: Homology modeling, virtual screening and structure-activity relationship analysis.
Sichuan University
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.
The Institute of Cancer Research
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
Identification of novel lysine demethylase 5-selective inhibitors by inhibitor-based fragment merging strategy.
Kyoto Prefectural University of Medicine
C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays.
Institute of Cancer Research
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
Potent and Selective KDM5 Inhibitor Stops Cellular Demethylation of H3K4me3 at Transcription Start Sites and Proliferation of MM1S Myeloma Cells.
University of Oxford
Structural analysis of human KDM5B guides histone demethylase inhibitor development.
University of Oxford